Cite

HARVARD Citation

    Dudnik, E. et al. (2018). Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). Lung cancer. pp. 117-124. [Online]. 
  
Back to record